Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

Glucagon receptor antagonists-4 is an selective antagonist of glucagon receptor.

GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.

Teduglutide , an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by inhibiting gastric emptying and secretion, which in turn reduces intestinal losses and promotes intestinal absorption.

L-168,049 is a very potent and selective, non-competitive antagonist of the human glucagon receptor with IC50 of 3.7 nM.

GLP-1(7-37) is an insulinotropic peptide generated from the precursor peptide GLP-1(1-37).

Adomeglivant is a potent and selective glucagon receptor antagonist that is used in clinical trial for type 2 diabetes mellitus.

Ubiquitin Isopeptidase Inhibitor I, G5 is an apoptosome-independent caspase and apoptosis activator.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.

PF-06882961 is a potent and orally bioavailable GLP-1R agonist.

Semaglutide is an analog of human GLP-1 with long-acting effect over the other GLP-1Ras.